Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 139

Sort by

Sort Order Select

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Donna Mastey, RN, Alexander M. Lesokhin, MD, Eric L Smith, MD PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X Lu, MD PhD, Meghan Salcedo, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Ciardiello, BS, Elizabeth Tavitian, BS, Tala Shekarkhand, BS, Even Rustad, MD, Venkata Yellapantula, PhD, Francesco Maura, MD, Tim J Peterson, PharmD, Sean M. Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, PhD, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio Giralt, MD, Neha Korde, MD

Blood (2019) 134 (Supplement_1): 3127.

https://doi.org/10.1182/blood-2019-125842

Published: 2019

Journal Articles

Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders

Mattia Algeri, MD, Stefania Galimberti, PhD, Maria Ester Bernardo, MD PhD, Attilio Rovelli, MD, Marco Zecca, MD, Giorgio La Nasa, MD, Sarah Marktel, MD, Pietro Merli, MD, Alice Bertaina, MD PhD, Daria Pagliara, MD PhD, Emilia Boccieri, MD, Francesca Del Bufalo, MD, Stefania Gaspari, MD, Giulia Capitoli, Maria Grazia Valsecchi, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 3280.

https://doi.org/10.1182/blood-2019-128925

Published: 2019

Journal Articles

Developing Single Cell Live Imaging Strategies to Determine MEP Fate and Predict Potential

Vanessa M Scanlon, PhD, Maria Kochugaeva, PhD, Juliana Xavier-Ferrucio, PhD, Yi-Chien Lu, PhD, Nayoung Kwon, Anisha Laumas, Matthew Cenci, Kalyani Lawrence, Katie Barden, Colin Holbrook, Andrew Tri Van Ho, PhD, Helen M. Blau, PhD, Andre Levchenko, PhD, Diane S. Krause, MD PhD

Blood (2019) 134 (Supplement_1): 1190.

https://doi.org/10.1182/blood-2019-131204

Published: 2019

Journal Articles

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Seth M Maliske, MD, Matthew J. Maurer, MS, Carrie A. Thompson, MD, Luis Porrata, MD, Ivana Micallef, MD, Rebecca L. King, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Margarida Magalhaes Silverman, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, David James J Inwards, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Patrick Johnston, MD PhD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 2896.

https://doi.org/10.1182/blood-2019-124579

Published: 2019

Journal Articles

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Anilkumar Gopalakrishnapillai, PhD, Colin Correnti, PhD, Anne Kisielewski, BS, Allison Kaeding, MD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 3925.

https://doi.org/10.1182/blood-2019-130941

Published: 2019

Journal Articles

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Siavash Piran, MDMSc,FRCPC, Michelle Zondag, BSN, RN, Drew Bednar, MD FRCSC, Brian Drew, MD FRCSC, Agnes Chmiel, MD FRCPC, Noel Chan, MBBS, MRCP, FRACP, FRCPA, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Sam Schulman, MD PhD FRCPC

Blood (2019) 134 (Supplement_1): 2434.

https://doi.org/10.1182/blood-2019-124601

Published: 2019

Journal Articles

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Blood (2019) 134 (Supplement_1): 2069.

https://doi.org/10.1182/blood-2019-127969

Published: 2019

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2019) 134 (Supplement_1): 781.

https://doi.org/10.1182/blood-2019-125204

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

Theodore Lee, MD, Sharon Pan, Wonkyung Byon, Bushra S Ilyas

Blood (2019) 134 (Supplement_1): 1152.

https://doi.org/10.1182/blood-2019-121542

Published: 2019

Journal Articles

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Valentina Ferrari, Tiffany N Tanaka, MD, Alison Tarke, Hanna Fields, Luca Ferrari, Alex Ni, Franco Ferrari, PhD, John Warner, PhD, Theresa Jochelson, Rafael Bejar, MD PhD, Antonella Vitiello, Dr. Pharm., Thomas A Lane, MD

Blood (2018) 132 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2018-99-118834

Published: 2018

Journal Articles

Very High Efficacy of Bendamustine, Gemcytabine and Dexamethasone (BGD) in Relapsed/Refractory Classical Hodgkin Lymphoma

Ryszard Swoboda, MD PhD, Jacek Najda, Katarzyna Dulik, Anna Kwiatkowska-Pamula, Maja Twardosz, Sebastian Giebel

Blood (2018) 132 (Supplement 1): 5366.

https://doi.org/10.1182/blood-2018-99-113904

Published: 2018

Journal Articles

An Enhanced Sensitivity DNA Sequencing Protocol for the Detection in AML of Measurable Residual Disease (MRD) Applicable for All Mutations

Hugh Y. Rienhoff, Jr., MD, Georges Natsoulis, PhD, Amber Jones, MA, Jennifer Peppe, BS, Ru Cao, PhD, Khalid Hanif, PhD, Justin M. Watts, MD

Blood (2018) 132 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2018-99-115505

Published: 2018

Journal Articles

Januskinase-2 V617F Positive Myeloproliferative Neoplasms and Haemostatic Disorders: Importance of Obesity in Prediction of Thrombotic Events

Marta Pires De Lima, MD, Maria Eduarda Couto, MD, Jorge Coutinho, MD, Maria Gomes da Silva, MD PhD, Fernanda Leite, MD PhD

Blood (2018) 132 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2018-99-112297

Published: 2018

Journal Articles

Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study

Blood (2018) 132 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2018-99-114311

Published: 2018

Journal Articles

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Hang Quach, MD FRACP, FRCPA, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP, FRCPA, MPhil, BA, Flora Yuen, BBiomedSc, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Edward S. Morris, BMBS, DM, Anna Kalff, MBBS, Krystal Bergin, Shreerang Sirdesai, MBBS, FRACP, FRCPA, Malgorzata Gorniak, BSc, Sridurga Mithraprabhu, PhD MSc, Tiffany Khong, BSc, PhD, John Reynolds, PhD

Blood (2018) 132 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2018-99-113982

Published: 2018

Journal Articles

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Blood (2018) 132 (Supplement 1): 257.

https://doi.org/10.1182/blood-2018-99-111321

Published: 2018

Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Shohei Mizuno, MD PhD, Koji Kawamura, MD PhD, Ichiro Hanamura, MD PhD, Kazutaka Sunami, MD PhD, Takehiko Mori, MD PhD, Fumihiko Nakamura, Shinsuke Iida, MD PhD, Hideyuki Nakazawa, PhD MD, Masanori Makita, Shinichi Kako, MD, Masashi Sawa, MD PhD, Yasunori Ueda, MD PhD, Hiroyuki Takahashi, MD PhD, Yoshinobu Kanda, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Hiroyuki Takamatsu, MD PhD, Akiyoshi Takami, MD

Blood (2018) 132 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2018-99-109905

Published: 2018

NARROW

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders

Developing Single Cell Live Imaging Strategies to Determine MEP Fate and Predict Potential

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Very High Efficacy of Bendamustine, Gemcytabine and Dexamethasone (BGD) in Relapsed/Refractory Classical Hodgkin Lymphoma

An Enhanced Sensitivity DNA Sequencing Protocol for the Detection in AML of Measurable Residual Disease (MRD) Applicable for All Mutations

Januskinase-2 V617F Positive Myeloproliferative Neoplasms and Haemostatic Disorders: Importance of Obesity in Prediction of Thrombotic Events

Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only